Surovkina M S, Semenova L V, Semenov V I, Lapshina I M, Volkova T V
Biull Eksp Biol Med. 1985 Aug;100(8):249-52.
Based on a study of the kininogenase activity of the total plasma kallikrein in the presence of 3 concentrations of the soybean inhibitor trypsin (0.5, 1.0, 10.0 micrograms/ml) one can measure at a time the activity of tissue kallikrein (without specifying the source) and the activity of 3 forms of plasma kallikrein, including its adsorption on kaolin that characterizes the conformational structure of the enzyme. Examination of 10 healthy subjects and 136 patients revealed a 10 to 20-fold increase in the content of tissue kallikrein in plasma of 70% of diabetes mellitus patients and a 2.5 to 3-fold elevation in 50% of patients with chronic occupational bronchitis, and in 30% of patients suffering from chronic hepatitis. The method suggested makes it possible to have a better insight into the physiological and pathogenetic role of the kinin system and may be used for laboratory control over the treatment efficacy.
基于在3种浓度的大豆胰蛋白酶抑制剂（0.5、1.0、10.0微克/毫升）存在的情况下对总血浆激肽释放酶激肽原酶活性的研究，人们可以一次性测定组织激肽释放酶（不指明来源）的活性以及3种形式的血浆激肽释放酶的活性，包括其在高岭土上的吸附情况，这表征了该酶的构象结构。对10名健康受试者和136名患者的检查发现，70%的糖尿病患者血浆中组织激肽释放酶含量增加了10至20倍，50%的慢性职业性支气管炎患者升高了2.5至3倍，30%的慢性肝炎患者也有升高。所建议的方法能够更深入地了解激肽系统的生理和发病机制作用，并且可用于对治疗效果进行实验室监测。
